BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 33116828)

  • 1. Programmed Death-1 Receptor (PD-1) as a Potential Prognosis Biomarker for Ovarian Cancer Patients.
    Pawłowska A; Suszczyk D; Tarkowski R; Paduch R; Kotarski J; Wertel I
    Cancer Manag Res; 2020; 12():9691-9709. PubMed ID: 33116828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic and Clinical Value of Interleukin 6 and CD45
    Wertel I; Suszczyk D; Pawłowska A; Bilska M; Chudzik A; Skiba W; Paduch R; Kotarski J
    J Immunol Res; 2020; 2020():1715064. PubMed ID: 33062717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian Cancer Patients.
    Pawłowska A; Kwiatkowska A; Suszczyk D; Chudzik A; Tarkowski R; Barczyński B; Kotarski J; Wertel I
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Th17 Cells and IL-17 As Novel Immune Targets in Ovarian Cancer Therapy.
    Bilska M; Pawłowska A; Zakrzewska E; Chudzik A; Suszczyk D; Gogacz M; Wertel I
    J Oncol; 2020; 2020():8797683. PubMed ID: 32148497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1.
    Okła K; Rajtak A; Czerwonka A; Bobiński M; Wawruszak A; Tarkowski R; Bednarek W; Szumiło J; Kotarski J
    J Transl Med; 2020 Jun; 18(1):220. PubMed ID: 32487171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Novel miRNAs as Potential Regulators of PD-1/PD-L1 Immune Checkpoint, and Prognostic Value of MIR9-1 and MIR124-2 Methylation in Ovarian Cancer].
    Kushlinskii NE; Loginov VI; Utkin DO; Filippova EA; Burdennyy AM; Korotkova EA; Pronina IV; Lukina SS; Smirnova AV; Gershtein ES; Braga EA
    Mol Biol (Mosk); 2020; 54(6):990-996. PubMed ID: 33276362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy.
    Khan M; Zhao Z; Arooj S; Fu Y; Liao G
    Front Immunol; 2020; 11():587460. PubMed ID: 33329567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of CD38 and CD101 expression in PD-1
    Zhou J; Wang W; Liang Z; Ni B; He W; Wang D
    Oncol Lett; 2020 Jul; 20(1):724-732. PubMed ID: 32565998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Programmed cell death protein 1 and its ligands regulate immune balance in allergic rhinitis].
    Wen SL; Li F; Zhao F; Zuo JJ; Deng YQ; Zhang W; Tao ZZ
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Apr; 55(4):384-390. PubMed ID: 32306637
    [No Abstract]   [Full Text] [Related]  

  • 10. Carboplatin and programmed death-ligand 1 blockade synergistically produce a similar antitumor effect to carboplatin alone in murine ID8 ovarian cancer model.
    Zhu X; Xu J; Cai H; Lang J
    J Obstet Gynaecol Res; 2018 Feb; 44(2):303-311. PubMed ID: 29171115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression.
    Shigemori T; Toiyama Y; Okugawa Y; Yamamoto A; Yin C; Narumi A; Ichikawa T; Ide S; Shimura T; Fujikawa H; Yasuda H; Hiro J; Yoshiyama S; Ohi M; Araki T; Kusunoki M
    Ann Surg Oncol; 2019 Mar; 26(3):876-883. PubMed ID: 30565045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
    Mortensen JB; Monrad I; Enemark MB; Ludvigsen M; Kamper P; Bjerre M; d'Amore F
    Eur J Haematol; 2021 Jul; 107(1):81-91. PubMed ID: 33721375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased Soluble PD-L1 Levels in the Plasma of Patients with Epithelial Ovarian Cancer Correlate with Plasma Levels of
    Koukourakis MI; Kontomanolis E; Sotiropoulou M; Mitrakas A; Dafa E; Pouliliou S; Sivridis E; Giatromanolaki A
    Anticancer Res; 2018 Oct; 38(10):5739-5745. PubMed ID: 30275195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma.
    Chang B; Huang T; Wei H; Shen L; Zhu D; He W; Chen Q; Zhang H; Li Y; Huang R; Li W; Wu P
    Cancer Immunol Immunother; 2019 Mar; 68(3):353-363. PubMed ID: 30506460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expression of soluble programmed death-1, soluble programmed death ligand 1 proteins and immune status in patients with oral lichen planus].
    Luo L; Shu M; Li S; Cai Y
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2015 Oct; 50(10):585-9. PubMed ID: 26757624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
    Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Percentages of PD-1
    Wang Y; Pang N; Wang X; Liu Y; Wang X; Wang L; Sun M; Yasen H; Zhao F; Fan W; Guo X; Ding J
    Hum Vaccin Immunother; 2018 Apr; 14(4):832-838. PubMed ID: 29333980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer.
    Zhu X; Lang J
    J Gynecol Oncol; 2017 Sep; 28(5):e64. PubMed ID: 28657225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma: A systematic review and meta-analysis.
    Huang LJ; Deng XF; Chang F; Wu XL; Wu Y; Diao QZ
    Medicine (Baltimore); 2018 Oct; 97(43):e12858. PubMed ID: 30412078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.